Metabolic & Weight Management
Exenatide
Also known as Byetta · Bydureon · exendin-4
Clinically studiedSubcutaneous injectionFDA-approved (Byetta and Bydureon for type 2 diabetes). The extended-release form carries a boxed warning for thyroid C-cell tumor risk seen in rodents.
Exenatide is a GLP-1 receptor agonist derived from exendin-4, a peptide originally identified in the saliva of the Gila monster. It enhances glucose-dependent insulin secretion, suppresses glucagon, and slows gastric emptying. It was one of the first incretin-based therapies and exists in twice-daily and extended-release once-weekly forms.
Studied / used for
- studied for glycemic control in type 2 diabetes
- used in protocols where modest weight reduction is a secondary effect
Commonly reported side effects
- nausea
- vomiting
- diarrhea
- constipation
- headache
- injection-site nodules (extended-release form)
Clinically studied. Supported by human clinical trials. This reflects the strength of the research base, not effectiveness or a recommendation.
Not medical advice.
This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.